Preliminary study on human papilloma virus 16 and Epstein-Barr virus infections in breast cancer patients
Chenyang He,Ting Wang,Yonggang Lyu,Juliang Zhang,Yongping Li,Ge Zhao,Fucheng Ma,Jiayun Liu,Jianghao Chen,Ling. Wang
DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2014.05.003
2014-01-01
Abstract:Objective To explore the expression of human papilloma virus 16 (HPV16) and Epstein-Barr virus( EBV) in different pathological types of breast cancer and breast benign lesions. Methods We analyzed the samples from 90 cases of different pathological types of breast cancer ( including 40 cases of invasive ductal carcinoma, 30 invasive lobular carcinoma and 20 carcinoma in situ), 20 cases of mammary fibroma and 10 cases of normal breast tissues. All specimens were collected from the patients treated in our hospital from June 2013 to June 2014. PCR was performed to amplify E6 gene site of HPV16 and the repeated sequence BamHIW of EBV. The expressions of HPV16 and latent membrane protein 1 (LMP-1) of EBV were detected by immunohistochemical staining to determine whether existed HPV16 or EBV infections, and the positive rate was calculated accordingly. The detection rate of virus between different pathological types of breast cancer and the detection rate of virus between PCR detection and immunohistochemistry was compared by χ2 test;the proportion of HPV16 positive cells and the proportion of EBV positive cells among different pathological types of breast cancer was compared by analysis of variance and Bonferroni pairwise comparison. Results PCR showed that HPV16 detection rate was 44. 44% (40/90) in breast cancer, 5% (1/20) in mammary fibroma and 0 in normal breast tissues; EBV detection rate was 43. 33% ( 39/90 ) in breast cancer, 0 in mammary fibroma and normal breast tissues; there were no statistically significant difference in the detection rate of HPV16 and EBV between different pathological types of breast cancer (χ2= 1. 238, P=0. 539; χ2= 1. 867, P=0. 393). Immunohistochemistry showed that HPV16 detection rate was 42. 22% (38/90) in breast cancer, 5% (1/20) in mammary fibroma and 0 in normal breast tissues; EBV detection rate was 42. 22%(38/90) in breast cancer, 0 in mammary fibroma and normal breast tissues. The proportion of HPV16 positive cells was (29. 78±0. 38)% in invasive ductal carcinoma, (28. 31±0. 53)% in invasive lobular carcinoma, (51. 83± 0. 65)% in carcinoma in situ, suggesting a significant difference (F=537. 779, P=0. 000). The proportion of EBV positive cells was (29. 73±0. 51)%, (28. 14±0. 65)% and (51. 11±0. 68)% respectively, which was significantly different (F=427. 771, P=0. 000);the sample of carcinoma in situ showed the higher proportion of HPV16 and EBV positive cells, compared with other two pathological types(all P=0. 000). The detection rates of HPV16 or EBV by PCR and immunohistochemistry in breast cancer specimens were not significantly different (χ2=0. 090, P=0. 764; χ2=0. 023, P=0. 880). Conclusion The infection of HPV16 and EBV may be related to the occurrence of breast cancer, and the infection degree is probably related to the pathological types of breast cancer.